RNAC Logo

Cartesian Therapeutics, Inc. (RNAC) 

NASDAQ
Market Cap
$434.72M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
33 of 775
Rank in Industry
28 of 432

Largest Insider Buys in Sector

RNAC Stock Price History Chart

RNAC Stock Performance

About Cartesian Therapeutics, Inc.

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, …

Insider Activity of Cartesian Therapeutics, Inc.

Over the last 12 months, insiders at Cartesian Therapeutics, Inc. have bought $11.86M and sold $3.22M worth of Cartesian Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Cartesian Therapeutics, Inc. have bought $11.86M and sold $3.22M worth of stock each year.

Highest buying activity among insiders over the last 12 months: SPRINGER TIMOTHY A () — $23.54M. BARABE TIMOTHY C (director) — $190,500.

The last purchase of 58,295 shares for transaction amount of $1.06M was made by SPRINGER TIMOTHY A () on 2024‑11‑18.

List of Insider Buy and Sell Transactions, Cartesian Therapeutics, Inc.

2024-11-18SaleChief Technology Officer
34,400
0.134%
$18.39$632,641+0.97%
2024-11-18Purchase
58,295
0.2238%
$18.12$1.06M+2.50%
2024-11-15SaleChief Technology Officer
22,068
0.088%
$17.20$379,497
2024-11-15SaleChief Scientific Officer
16,065
0.0635%
$17.06$274,093
2024-11-15SaleChief Medical Officer
20,000
0.0795%
$17.14$342,888
2024-11-15Purchase
277,246
1.0985%
$17.09$4.74M
2024-11-14SaleChief Technology Officer
25,900
0.0987%
$16.44$425,9000.00%
2024-11-14SaleChief Scientific Officer
36,050
0.1393%
$16.67$600,9490.00%
2024-11-14SaleChief Medical Officer
35,000
0.1309%
$16.13$564,6450.00%
2024-11-14Purchase
96,399
0.3658%
$16.37$1.58M0.00%
2024-10-04Purchase
80,301
0.4883%
$22.58$1.81M-14.68%
2024-10-03Purchase
119,906
0.6423%
$19.89$2.38M-7.84%
2024-10-02Purchase
5,514
0.0258%
$17.38$95,822+17.51%
2024-08-12Purchasedirector
7,500
0.0353%
$12.70$95,250+33.86%
2024-08-12Purchase
8,016
0.0378%
$12.72$101,968+33.86%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.